NPS Pharmaceuticals announced that it has established a patient-centric distribution and clinical service network for Gattex (teduglutide [rDNA origin]) for Injection, as subcutaneous use. Gattex, a recombinant human GLP-2 analog, is indicated for treatment in adults with short bowel syndrome who are dependent on parenteral support.
The service network is comprised of specialty home infusion providers, including Accredo Health Group, Inc., BioScrip Inc., Coram, LLC, ThriveRx, and Walgreens Infusion Services. These contracted companies will dispense Gattex and provide clinical services to support its use in reducing dependence on parenteral nutrition and intravenous fluids for patients with short bowel syndrome.
Gattex will be available in the first quarter of 2013.
For more information call (855) 542-8839 or visit www.npsp.com/Gattex.